User:Mr. Ibrahem/Digoxin immune fab

From Wikipedia, the free encyclopedia
Mr. Ibrahem/Digoxin immune fab
Bottle of digoxin immune fab
Clinical data
Trade namesDigibind, DigiFab, others
Other namesDigoxin-specific antibody
AHFS/Drugs.comMonograph
Routes of
administration		IV infusion, injection
Pharmacokinetic data
Onset of action30 min[1]
Elimination half-life15 hours for DigiFab, 23 hours for Digibind
Duration of action15 to 20 hrs[1]
ExcretionKidney
Identifiers
  • Anti-digoxin antibody fragment
Chemical and physical data
FormulaC2085H3223N553O672S16
Molar mass47301.88 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Digoxin immune fab, sold under the brand name Digibind among others, is the antidote for digoxin toxicity.[2] It may also be used for toxicity from certain plants such as oleander or foxglove and for eclampsia.[2] It is given by injection into a vein.[2] Benefits occur within 30 minutes.[2]

Common side effects include low potassium and heart failure.[2] Other side effects may include allergic reactions including anaphylaxis.[2] When needed, it can be used during pregnancy or breastfeeding.[3] It works by binding to digoxin and similar compounds in the blood.[2]

Digoxin immune fab was approved for medical use in the United States in 1986.[4] In the United Kingdom one 40 mg vial cost the NHS about £750.[5] In the United States this amount costs about 4,200 USD as of 2021.[6] It is made from antibodies from sheep that have been immunized with a digoxin derivative.[2][7]

References[edit]

  1. ^ a b "digoxin immune Fab (ovine)". www.glowm.com. Archived from the original on 29 August 2021. Retrieved 8 September 2020.
  2. ^ a b c d e f g h i j "Digoxin Immune Fab Monograph for Professionals". Drugs.com. Archived from the original on 21 January 2021. Retrieved 22 July 2021.
  3. ^ Briggs, Gerald G.; Freeman, Roger K.; Yaffe, Sumner J. (2008). Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. Lippincott Williams & Wilkins. p. 542. ISBN 978-0-7817-7876-3. Archived from the original on 2021-08-28. Retrieved 2021-07-22.
  4. ^ Shagufta, Dr Chandrawati Jee; Jee, Chandrawati (2008). Textbook Of Biotechnology. APH Publishing. p. 117. ISBN 978-81-313-0367-2. Archived from the original on 2021-08-28. Retrieved 2021-07-22.
  5. ^ BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 1440. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)
  6. ^ "DigiFab Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 27 January 2021. Retrieved 22 July 2021.
  7. ^ Sealock, Kara; Seneviratne, Cydnee; Lilley, Linda Lane; Collins, Shelly Rainforth; Snyder, Julie S. (18 October 2020). Lilley's Pharmacology for Canadian Health Care Practice - E-Book. Elsevier Health Sciences. p. 417. ISBN 978-0-323-69481-0. Archived from the original on 29 August 2021. Retrieved 22 July 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Digoxin_immune_fab&oldid=1223963944"